Rocket Pharmaceuticals: FDA Validation, Non-Dilutive Funding Catalyst, and Pipeline De-Risking Support Buy Rating

LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Rocket Pharmaceuticals today and set a price target of $9.00.

Patrick Dolezal has given his Buy rating due to a combination of factors tied to Rocket’s recent regulatory and financial achievements. He views the FDA approval of Kresladi for LAD-I, based on robust biomarker improvements linked to survival and without the need for additional pivotal trials, as a critical validation of Rocket’s gene therapy platform and its regulatory execution.

At the same time, he highlights the rare pediatric disease priority review voucher as a major, non-dilutive funding catalyst, with expected monetization in the roughly $100–200M range. In his view, while direct Kresladi revenues will be modest and delayed, the approval materially de-risks the broader pipeline, supports sentiment around future cardiac gene therapies, and helps bridge Rocket’s roughly one-year cash runway without excessive dilution, together justifying a Buy recommendation.

In another report released today, Bank of America Securities also maintained a Buy rating on the stock with a $8.00 price target.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCKT in relation to earlier this year.